Anti-RAD51D Antibody Prodrug, Protease Activated (5A8/4)

The Anti-RAD51D Antibody Prodrug, Protease Activated (5A8/4) is an antibody prodrug comprised of a recombinant mouse antibody targeting human and hamster Rad51D, linked to a masking peptide that conceals the active antigen-binding site via a protease-cleavable linker. The mask peptide is recombinantly attached to the amino terminus of either the light or heavy chain of the antibody, designed to block access to the antigen-binding site and physically prevent the antibody from binding to RAD51D protein. Once the masking peptide is cleaved by matrix metalloproteinases (MMPs), the prodrug is activated, allowing the unmasked monoclonal antibody component to bind to RAD51D effectively. Rad51D is an essential component of the Homologous Recombination (HR) pathway, which is the high-fidelity mechanism used by cells to repair DNA double-strand breaks. Mutations in the RAD51D gene are classified as tumor suppressor defects and are associated with an increased, hereditary risk for developing cancers, primarily ovarian and breast cancer. These defects in DNA repair create a vulnerability in the tumor cell that can be therapeutically exploited using drugs such as PARP inhibitors (synthetic lethality).